BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update.

BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference.

Cancer-targeting biotech NovoCure (NVCR -9.00%) had some highly positive news from the laboratory to deliver earlier this week, and investors couldn't grab hold of the stock fast enough. This momentum...

The life science industry recently gave folks diagnosed with pancreatic cancer the best news this group has received in a very long time. A new treatment option that significantly raises their chances...

NovoCure's TTFields therapy, combined with standard chemotherapy, significantly improves overall survival in advanced pancreatic cancer, showing a 33% improvement in two-year survival rates. Despite p...

Novocure stock soars 49% as the late-stage study of TTFields therapy for treating pancreatic adenocarcinoma meets the primary endpoint of overall survival.

Positive results achieved from phase 3 PANOVA-3 study using TTFields + Gemcitabine + Nab-paclitaxel to treat unresectable, locally advanced 1st-line pancreatic cancer patients. Multiple regulatory sub...

On Monday, NovoCure Ltd NVCR and Zai Lab Limited ZLAB revealed topline data from the Phase 3 PANOVA-3 trial of Tumor-Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxe...

Novocure stock catapulted early Monday after the company's cancer-treating device succeeded in a study of patients with pancreatic cancer. The post Novocure Launches 40% After Pancreatic Cancer Treatm...

Novocure said on Monday its experimental therapy extended the lives of patients with a form of advanced pancreatic cancer when combined with chemotherapy, achieving the primary goal in a late-stage tr...

SHANGHAI & CAMBRIDGE, Mass. & ROOT, Switzerland--(BUSINESS WIRE)--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced today that the pivotal, Phase 3 PANOVA-3 trial met it...

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer.

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure to participate in upcoming investor conferences.

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure data at 2024 SNO annual meeting highlights product innovation and real-world evidence for TTFields therapy in glioblastoma.

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--FDA approves Novocure's Innovative HFE transducer arrays for use with Optune Gio® for glioblastoma.

NovoCure Limited (NASDAQ:NVCR ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Ingrid Goldberg - IR Bill Doyle - Chairman Ashley Cordova - CFO Asaf Danziger - CEO Fr...

NovoCure (NVCR) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.46 per share a year ago.

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Appoints Christoph Brackmann as Chief Financial Officer.

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Reports Third Quarter 2024 Financial Results.

On October 15th, NovoCure Limited received FDA approval of its lung cancer treatment which resulted in positive price action. The lung cancer market will significanly increase Novocure's scale, on top...